{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fquadshot-news-podcast.simplecast.com%2Fepisodes%2F11252024-real-time-31zt02pP","width":444,"version":"1.0","type":"rich","title":"11.25.2024 - Real Time","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/d4956b26-f7a3-4f47-a83d-9293649d65c8/ec08e780-4e06-4c01-8109-4e894d682296/qs_sqaure.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/beb36d0a-a668-4871-b7ed-1d3e0f1703f3\" height=\"200\" width=\"100%\" title=\"11.25.2024 - Real Time\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Check out this week's QuadCast where we highlight the reduced toxicity of reduced-margin MRI-guided prostate SBRT, the response rate of double hit lymphoma to radiation, the inappropriate radiation services denial rate of Medicare Advantage plans, and more!"}